An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Phase

Division (Location)

Study ID

NCT#

Brief Description
An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.